GlassScriptPhysician profile
Mark R Jackson
NPI 1033177530
$1,480.77
in general payments reported to CMS, 2019-2025
15 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $184 · 2021: $342 · 2022: $162 · 2023: $247 · 2024: $188 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $381.26 | 2021-2025 | Abre, Closurefast, Venaseal |
| Boston Scientific Corporation | $342.03 | 2020-2025 | Varithena Administration Pack |
| Bard Peripheral Vascular, INC. | $175.71 | 2020-2024 | Venclose Maven Catheter |
| Kowa Pharmaceuticals America, INC. | $116.16 | 2020-2021 | |
| Elutia, INC. | $90.04 | 2021-2023 | |
| Angiodynamics, INC. | $83.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $61.44 | 2021 | |
| Atricure, INC. | $57.64 | 2025 | Atricure Cryoice Cryosphere Cryoablation System, Synergy Ablation System |
| Biocompatibles, INC. | $55.68 | 2019 | |
| Supernus Pharmaceuticals, INC. | $43.37 | 2021 | |
| Medtronic Vascular, INC. | $26.44 | 2020 | |
| Nuvasive, INC. | $17.64 | 2019 | |
| Inari Medical, INC. | $13.87 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Ekos Corporation | $12.53 | 2019 | |
| Venclose INC. | $3.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.